Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 43, Issue 5, 2018, Pages 533-541

  Luedtke, Doreen ^a   Marzin, Kristell ^a   Jungnik, Arvid ^a   von Wangenheim, Ute ^a   Dallinger, Claudia ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ABC TRANSPORTER SUBFAMILY B; CYTOCHROME P450 3A4; KETOCONAZOLE; NINTEDANIB; POLFARMEX; RIFAMPICIN; INDOLE DERIVATIVE;

ABNORMAL FECES COMPOSITION; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; COMBINATION DRUG THERAPY; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EYE PAIN; FATIGUE; FEVER; FLATULENCE; FRACTION ABSORBED; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INFLUENZA; KIDNEY CONCENTRATING CAPACITY; LACERATION; MALE; MAXIMUM CONCENTRATION; MONOTHERAPY; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; PILOT STUDY; POLLAKISURIA; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER ABDOMINAL PAIN; URINE COLOR; URINE COMPOSITION DISORDER; XEROSTOMIA; ADOLESCENT; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOLOGICAL MODEL; DRUG ADMINISTRATION; DRUG INTERACTION; GERMANY; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GERMANY; HEALTHY VOLUNTEERS; HUMANS; INDOLES; INTESTINAL ABSORPTION; KETOCONAZOLE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RIFAMPIN; RISK ASSESSMENT; YOUNG ADULT;

EID: 85045137984     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-018-0467-9     Document Type: Article

References (17)

1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–82
2. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, Roth M. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:157
3. Boehringer Ingelheim Pharmaceuticals, Inc. (2017). OFEV™ (nintedanib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205832s004lbl.pdf. Accessed 27 Apr 2017
4. Boehringer Ingelheim (2015). OFEV (nintedanib) summary of product characteristics. February 2017. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf. Accessed 27 Apr 2017
5. Boehringer Ingelheim International GmbH (2015). Vargatef (nintedanib) summary of product characteristics. March 2017. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002569/WC500179970.pdf. Accessed 27 Apr 2017
6. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16:311–9
7. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9:2825–33
8. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22:1374–81
9. Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol. 2016;56:1387–94
10. Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Klueglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–92
11. Stopfer P, Rathgen K, Bischoff D, Lüdtke S, Marzin K, Kaiser R, Wagner K, Ebner T. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297–311
12. Food and Drug Administration (FDA). Guidance for industry: drug interaction studies–study design, data analysis, implications for dosing, and labeling recommendations. February 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 4 Mar 2016
13. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol. 1999;39:487–94
14. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet. 2008;23:14–21
15. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14851–7
16. Brault M. Development and validation of an LC-MS/MS method for the quantification of cortisol and 6-beta-hydroxycortisol in human urine. SGS Cephac Europe Analytical Report Reference No. CP095124, 01 Sept 2010
17. Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol. 2008;66:215–21